Wyeth | Org Chart | Contact Info

Business Wire

Business Wire - The global leader in news distribution

Pfizer Receives FDA Approval to Extend Use of Prevnar 13® for Prevention of Pneumococcal Pneumonia and Invasive Disease in Adults 50 Years and Older
Friday December 30th 2011 03:47:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae)

Pfizer Reports Results From Three Phase 4 Studies Demonstrating EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact On Drug Liking And Withdrawal Symptoms
Thursday December 22nd 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today results from three Phase 4 studies of EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII designed to assess the effect of the drug when crushed and taken either orally or intranasally. Studies ALO-01-10-4005 and ALO-01-10-4004 were double-blind cross-over designed studies in non-dependent, recreational opioid users that compared subjective measures relating to abuse potential of crushed EMBEDA t

(image/jpeg)

Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts
Tuesday December 20th 2011 10:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2012. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Qu

(image/jpeg)

Pfizer Announces FDA Acceptance For Review Of New Drug Application For Tofacitinib For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Tuesday December 20th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in August 2012 for the NDA. Pfizer has

(image/jpeg)

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Restless Legs Syndrome
Friday December 16th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study for Lyrica (pregabalin) in patients with Restless Legs Syndrome (RLS) met each of its three co-primary endpoints, showing significant benefit as compared with placebo and pramipexole. Pfizer will continue to further analyze these top-line results. The study, A0081186, was a randomized, double-blind, 12-month trial. It enrolled more than 700 patients, who received either a placebo, Lyrica at 300 mg/day, pramip

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabaline) Capsules CV In Restless Legs Syndrome
Friday December 16th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study for Lyrica (pregabalin) in patients with Restless Legs Syndrome (RLS) met each of its three co-primary endpoints, showing significant benefit as compared with placebo and pramipexole. Pfizer will continue to further analyze these top-line results. The study, A0081186, was a randomized, double-blind, 12-month trial. It enrolled more than 700 patients, who received either a placebo, Lyrica at 300 mg/day, pramip

(image/jpeg)

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (prebabalin) Capsules CV In Restless Legs Syndrome
Friday December 16th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study for Lyrica (pregabalin) in patients with Restless Legs Syndrome (RLS) met each of its three co-primary endpoints, showing significant benefit as compared with placebo and pramipexole. Pfizer will continue to further analyze these top-line results. The study, A0081186, was a randomized, double-blind, 12-month trial. It enrolled more than 700 patients, who received either a placebo, Lyrica at 300 mg/day, pramip

(image/jpeg)

Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries
Friday December 16th 2011 07:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company’s commitment to help protect millions of infants and young children in the developing world from pneumococcal disease – the leading cause of vaccine-preventable death in young children. Pfizer is now committed to supply up to a total of 480 million doses of Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent,

(image/jpeg)

Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries
Friday December 16th 2011 07:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company’s commitment to help protect millions of infants and young children in the developing world from pneumococcal disease – the leading cause of vaccine-preventable death in young children. Pfizer is now committed to supply up to a total of 480 million doses of Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent,

(image/jpeg)

New Survey Reveals Top Misperceptions Parents Have When Treating Their Child’s Fever
Tuesday December 13th 2011 08:00:00 AM

MADISON, N.J.--(BUSINESS WIRE)--Tis’ the season for sneezing, coughing and fevers. As the temperature drops and cold and flu season gets under way, parental anxiety is expected to rise. According to two new surveys of parents and pediatricians from Pfizer Consumer Healthcare, makers of Children’s Advil®, more than half of all parents report feeling anxious, fearful or helpless when their child comes down with a fever. In addition, many parents are not managing the fever correctly. This is nothin

(image/jpeg)

Pfizer Elects CEO Ian Read As Chairman Of The Board
Monday December 12th 2011 03:16:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has elected current President and Chief Executive Officer, Ian Read, as Chairman of the Board and Chief Executive Officer, effective immediately. Mr. Read succeeds George Lorch as Chairman of the Board. The independent members of the board named Mr. Lorch as Lead Independent Director. “Over the past year, Ian has clearly demonstrated the leadership and vision necessary to drive Pfizer’s strategies and

(image/jpeg)

Pfizer Declares A 22-Cent First-Quarter 2012 Dividend
Monday December 12th 2011 11:24:00 AM

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 22-cent first-quarter 2012 dividend on the company’s common stock, payable March 6, 2012, to shareholders of record at the close of business on February 3, 2012. Pfizer increased the dividend by 10 percent, to 22 cents from 20 cents per share. The first-quarter 2012 cash dividend will be the 293rd consecutive quarterly dividend paid by Pfizer. The board of directors also authorized a new share repurchas

(image/jpeg)

Jon Bon Jovi Reveals His True Advil® Story
Friday December 9th 2011 08:01:00 AM

MADISON, N.J.--(BUSINESS WIRE)--Jon Bon Jovi’s schedule is packed - on any given day he’s performing sold-out stadium shows, staying fit with daily runs, spending time with his family and giving back through the Jon Bon Jovi Soul Foundation. One thing that’s not on his schedule is pain. The artist gives a glimpse into his life in a new advertisement for Advil®. The TV ad was shot in Red Bank, New Jersey, at the Jon Bon Jovi Soul Kitchen, a community kitchen that recently opened as an initiative

(image/jpeg)

Jon Bon Jovi Reveals His True Advil® Story
Thursday December 8th 2011 08:01:00 PM

MADISON, N.J.--(BUSINESS WIRE)--Jon Bon Jovi’s schedule is packed - on any given day he’s performing sold-out stadium shows, staying fit with daily runs, spending time with his family and giving back through the Jon Bon Jovi Soul Foundation. One thing that’s not on his schedule is pain. The artist gives a glimpse into his life in a new advertisement for Advil®. The TV ad was shot in Red Bank, New Jersey, at the Jon Bon Jovi Soul Kitchen, a community kitchen that recently opened as an initiative

(image/jpeg)

The Advil® Congestion Relief Project Tackles Congestion in Chicago, the Country’s #1 City for Traffic Congestion*
Thursday December 8th 2011 10:08:00 AM

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, stopped in Westside Chicago yesterday as part of a nationwide effort to help communities fight congestion. Chicago ranks #1 in the country for traffic congestion*, and to help alleviate congestion on busy roads this winter, Advil® Congestion Relief donated snow removal equipment specifically for the newly-established protected bicycle lanes, an initiative of Mayor Rahm Emanuel. Chicago Bears legen

(image/jpeg)

FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma (RCC) To Be Favorable
Wednesday December 7th 2011 11:42:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) voted unanimously 13 to 0 that data for the investigational agent axitinib support a favorable benefit/risk profile for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of a first-line systemic therapy. The ODAC panel’s recommendation will be considered by the FDA when making its decision regarding Pfizer’s New Drug

(image/jpeg)

Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
Monday December 5th 2011 05:03:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 – Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. The study met its primary endpoint: treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urgency urinary incontinence (UUI) episodes per day at the end of treatment.

(image/jpeg)

Pfizer Completes Acquisition of Excaliard
Friday December 2nd 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. “It is imperative at Pfizer that we continue to develop new and innovative treatments to address unmet medical needs, and there is currently no FDA-approved treatment for excessive skin scarring,” said

(image/jpeg)

Pfizer Completes Acquisition of Ferrosan Consumer Health’s Business
Thursday December 1st 2011 05:30:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has completed its previously announced acquisition of Ferrosan Consumer Health’s business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited. “Ferrosan Consumer Health’s innovative products and geographic footprint are a strong fit for our business,” said Paul Sturman, President, Pfizer Consumer Healthcare. “Today, we have taken an important step by adding leading brands to our exis

(image/jpeg)

New Research Initiative Examines Economic Impact of Smoke-free Policies on Restaurants and Bars
Wednesday November 30th 2011 04:26:00 PM

ATLANTA--(BUSINESS WIRE)--As part of ongoing efforts to reduce disease and death caused by smoking and secondhand smoke exposure, the CDC Foundation and CDC have launched a new initiative to study the economic impact of smoke-free policies on restaurants and bars in nine states. Previous research shows that smoke-free policies that prohibit smoking in workplaces and public places, including restaurants and bars, reduce nonsmokers’ exposure to secondhand smoke and help employees who smoke to quit

FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Tuesday November 29th 2011 09:14:00 AM

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The FDA accepted the filing and assigned a priority-review designation. The Prescription Drug User Fee Act (PDUFA) goal date f

Pfizer to Acquire Excaliard Pharmaceuticals
Tuesday November 22nd 2011 07:30:00 AM

NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year. Excaliard’s lead product, EXC 001, an antisense oligonucleotide in p

(image/jpeg)

Pfizer And MIT Break Ground On New Research Units In Kendall Square
Monday November 21st 2011 11:00:00 AM

NEW YORK and CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. and the Massachusetts Institute of Technology (MIT) today held the official groundbreaking of the new location of Pfizer's Cardiovascular, Metabolic and Endocrine Diseases (CVMED) and Neuroscience research units at 610 Main Street, Cambridge, MA. In September, Pfizer announced it had entered into a 10-year lease agreement with MIT for more than 180,000 square feet. Taking part in the groundbreaking event were: Pfizer Board Member Dennis

(image/jpeg)

Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis
Monday November 21st 2011 05:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA). Validation means that the EMA has confirmed that the application is complete and the agency is beginning its review procedure. Pfizer studied tofacitinib for moderate-to-

(image/jpeg)

Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program
Friday November 18th 2011 09:28:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center’s Corporate Citizenship Award in the Best International Ambassador category for Pfizer’s Global Health Partnerships program. The “Citizens” Awards honor excellence in corporate citizenship and civic leadership for initiatives in both the United States and across the world. “The essence of a successful corporate social responsibility program is when it becomes a model that other c

(image/jpeg)

Pfizer’s Vyndaqel® (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)
Thursday November 17th 2011 06:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the European Commission has approved Vyndaqel® (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. TTR-FAP is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide. 1,2,3 “A diagnosis of TTR-FAP, usually made in patients during their mid-life years, impacts both the physical and emotional well-

(image/jpeg)

The Advil® Congestion Relief Project Hits the Road to Relieve Congestion in Communities
Wednesday November 16th 2011 12:37:00 PM

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, yesterday, kicked off a nationwide effort to make a difference in communities. The cold and flu brand is putting a twist on its tagline – “The Right Relief for the Real Problem,” and providing literal relief in congested places across the US. In its first relief stop, The Advil® Congestion Relief Project unveiled a new library at P.S. 130 in the Bronx. Yankee fan favorite Brett Gardner helped unve

(image/jpeg)

Kathryn Joosten Speaks Out About Lung Cancer Profiles; ‘Desperate’ to Share Her Personal Lung Cancer Story to Help Others
Monday November 14th 2011 01:01:00 PM

NEW YORK--(BUSINESS WIRE)--Kathryn Joosten, two-time Emmy® Award-winning actress and star of Desperate Housewives and The West Wing, is opening up about her 10-year battle with lung cancer as part of a new national campaign, Lung Cancer Profiles. Lung Cancer Profiles aims to reduce the stigma associated with lung cancer by educating about the diversity of the disease inside and out. The campaign, created by Pfizer Oncology in collaboration with the nation’s leading lung cancer advocacy groups, a

(image/jpeg)

New Data Presented On Phase 3 Trial Of ELIQUIS® (apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical Illness
Sunday November 13th 2011 08:01:00 AM

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30. The apixaban arm had a 13 percent lower rate

(image/jpeg)

Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency
Tuesday November 8th 2011 07:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency. The study met its primary endpoint, as treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urinary urgency episodes overnight during sleep hours after 12 weeks of treatment.

(image/jpeg)

Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd Annual Meeting Of The American Society Of Hematology
Monday November 7th 2011 02:00:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML),1 inotuzumab in non-Hodgkin lymphoma (NHL),2 as well as the first presentation of clinical data for PF-04449913,3 which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.4 In addition, ongoing investigator-initiated research on gemtuzumab ozogamicin (Mylotarg) will be presented in

(image/jpeg)

Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients with Moderately Active Disease
Saturday November 5th 2011 05:20:00 PM

THOUSAND OAKS, Calif. & NEW YORK--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate (MTX) in Period one and were randomized to continue on ENBREL plus MT

Pfizer Reports Third-Quarter 2011 Results
Tuesday November 1st 2011 07:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter(4) Year-to-Date(4) 2011 2010 Change 2011 2010 Change Reported Revenues $ 17,193 $ 15,995 7 % $ 50,679 $ 49,703 2 % Adjusted Income(1) 4,820 4,352 11 % 14,354 14,141 2 % Adjusted Diluted EPS(1) 0.62 0.54 15 % 1.81 1.75 3 % Reported Net Income(2) 3,738 866 * 8,570 5,367 60 % Reported Diluted EPS(2) 0.48 0.11 * 1.08 0.66 64 % See end of te

(image/jpeg)

Pfizer Reports Third-Quarter 2011 Results
Tuesday November 1st 2011 07:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter(4) Year-to-Date(4) 2011 2010 Change 2011 2010 Change Reported Revenues $ 17,193 $ 15,995 7 % $ 50,679 $ 49,703 2 % Adjusted Income(1) 4,820 4,352 11 % 14,354 14,141 2 % Adjusted Diluted EPS(1) 0.62 0.54 15 % 1.81 1.75 3 % Reported Net Income(2) 3,738 866 * 8,570 5,367 60 % Reported Diluted EPS(2) 0.48 0.11 * 1.08 0.66 64 % See end of te

(image/jpeg)

Pfizer Completes Acquisition Of Icagen
Friday October 28th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer. Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6.00 in cash, without interest thereon, and less any applicable withholding and transfer

(image/jpeg)

Pfizer Declares A 20-Cent Fourth-Quarter 2011 Dividend
Thursday October 27th 2011 09:37:00 AM

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent fourth-quarter 2011 dividend on the company’s common stock, payable December 6, 2011, to shareholders of record at the close of business on November 11, 2011. The fourth-quarter 2011 cash dividend will be the 292nd consecutive quarterly dividend paid by Pfizer.

(image/jpeg)

Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease
Thursday October 27th 2011 05:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved the Company’s pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older. “Prevenar 13, the first and only pneumococcal conjugate vaccine approved by the European Commission for use in adul

(image/jpeg)

Pfizer Establishes Precision Medicine Research Collaboration With Medco
Wednesday October 26th 2011 04:00:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has established a research collaboration with Medco Health Solutions, Inc. (NYSE: MHS) and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes. The collaboration is intended to enhance Pfizer’s precision medicine approach, which integrates genomic and phenotypic information, to help

(image/jpeg)

Peggy Fleming and the Makers of Robitussin® Provide Relief this Cold and Flu Season with a Simple Question: "Does Your Last Name Sound Contagious?"
Wednesday October 26th 2011 09:25:00 AM

MADISON, N.J.--(BUSINESS WIRE)--This week, Robitussin® marked the start of another cold and flu season by shaking up the most contagious months of the calendar year for America’s “sick but can’t stop” sufferers with the launch of the Simple Acts of Relief program. To kick-off the launch of the program, Robitussin® has teamed up with iconic Olympic and World ice skating champion and sports commentator, Peggy Fleming. As the “simplest” act of relief, the makers of Robitussin® and Ms. Fleming are m

(image/jpeg)

Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search
Wednesday October 26th 2011 08:00:00 AM

GENEVA--(BUSINESS WIRE)--The World Intellectual Property Organization (WIPO), in an unprecedented collaboration with leading pharmaceutical companies and BIO Ventures for Global Health (BVGH), launched today WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat neglected tropical diseases, malaria, and t

Pfizer Invites Public to View and Listen to Webcast of November 6 Pfizer Analyst and Investor Meeting at ACR
Monday October 24th 2011 10:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s specialty care leadership team at an analyst and investor meeting on Sunday, November 6, 2011 at 6:30 p.m. Central Standard Time, in connection with the annual meeting of the American College of Rheumatology (ACR). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Analyst and Investor Meeting at ACR” link in T

(image/jpeg)

Additional Data From Pfizer’s Prevnar 13® Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of America
Friday October 21st 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional data from several clinical studies of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), which is being held Oct. 20-23, 2011, in Boston, Mass. The data from these studies provide support for the pending regulatory applications for the use of

(image/jpeg)

Pfizer Animal Health and the Resource Foundation Expand Initiative to Increase Productivity of Small Family Farms in Latin America and India
Tuesday October 18th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health and The Resource Foundation announced today the expansion of a comprehensive education and training program to increase the capacity, productivity and quality of life of rural farmers in eight Latin American countries. Plans call for tailoring the program to the needs of rural communities in India. The agreement was guided by results of a decade-long collaboration also announced today. Pfizer Animal Health and the Pfizer Foundation have committed $

(image/jpeg)

Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for Seniors
Thursday October 13th 2011 03:00:00 PM

LOUISVILLE, Ky. & NEW YORK--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) and Pfizer Inc. (NYSE: PFE) today announced a five-year research partnership to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other populations. Humana, one of the nation’s largest health care companies, and Pfizer, the world’s largest biopharmaceutical company, will bring together researchers and health care experts from both organizations to st

(image/jpeg)

Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor
Wednesday October 5th 2011 05:01:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today an agreement with Puma Biotechnology, Inc. for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, being studied for the treatment of cancer. Under the terms of the agreement, Puma will assume sole responsibility for global development and commercialization of neratinib. Pfizer will be entitled to receive payments upon Puma’s achieve

(image/jpeg)

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts
Monday October 3rd 2011 10:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Qua

(image/jpeg)

Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award Ceremony
Friday September 30th 2011 05:36:00 PM

NEW YORK--(BUSINESS WIRE)--The Prix Galien USA committee recognized excellence in scientific innovation that improves the state of human health last night during the fifth annual Prix Galien Awards Gala. The Pro Bono Humanum Award and the Prix Galien USA 2011 Awards for best biotechnology product and best pharmaceutical agent were presented at a ceremony held at the Museum of Natural History in New York City. The Prix Galien USA 2011 Award selection committee is an unrivaled network that include

Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND® (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive Aspergillosis
Friday September 30th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND® (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis (IA), a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems. The primary analysis of this double-blinded prospective randomized clinical trial was

(image/jpeg)

The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online
Thursday September 29th 2011 09:06:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and the National Association of Boards of Pharmacy® (NABP) are launching a new effort to draw attention to the risks associated with counterfeit prescription medicines and help patients learn how to safely buy medicines online. Prescription medicines are among the most counterfeited consumer goods. Worldwide sales of counterfeit medicines were estimated to exceed $75 billion last year – an increase of 90 percent since 2005. Last year, one in six

(image/jpeg)

Even Famous Faces Have an Advil® Story to Share
Thursday September 22nd 2011 10:52:00 AM

MADISON, N.J.--(BUSINESS WIRE)--After a day on the tennis court with his doubles partner and wife, Joy, Regis Philbin takes Advil® to relieve the pain that comes from a long match. Just like millions of Americans who rely on Advil® to relieve their tough pain, Regis and Joy have real stories to tell about how Advil® helps them keep doing what they love. The Philbins are the first famous faces to join real Advil® users who share their Advil® stories. The advertisements, which focus on the Philbin

(image/jpeg)

New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial Hyperplasia
Thursday September 22nd 2011 08:00:00 AM

WASHINGTON--(BUSINESS WIRE)--Pfizer Inc. will announce new one-year results from the Selective estrogens, Menopause, And Response to Therapy [SMART]-5 Phase 3 study of the safety and efficacy of the investigational tissue selective estrogen complex (TSEC) bazedoxifene/conjugated estrogens (BZA/CE) at the 22nd annual meeting of the North American Menopause Society (NAMS), September 21-24 in Washington, D.C. BZA/CE is being developed by Pfizer for the treatment of moderate-to-severe hot flashes, v

(image/jpeg)

Pfizer Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc.
Tuesday September 20th 2011 08:00:00 AM

NEW YORK & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today the expiration of the subsequent offering period of the cash tender offer by Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), for all of the outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The subsequ

(image/jpeg)

Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.
Tuesday September 13th 2011 08:00:00 AM

NEW YORK and RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of the subsequent offering period of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. T

(image/jpeg)

Pfizer to Present Clinical Data from Oncology Portfolio at the 2011 European Multidisciplinary Cancer Congress
Tuesday September 13th 2011 06:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer’s renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT® (sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 – 27, 2011. “As SUTENT changed the treatment landscape for patients wit

(image/jpeg)

Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In China
Thursday September 8th 2011 05:01:00 PM

MADISON, N.J. & HUINAN, China--(BUSINESS WIRE)--Pfizer Animal Health, a business unit of Pfizer Inc. (NYSE: PFE), and Jilin Guoyuan Animal Health Company, Ltd., an innovator in animal health vaccines based in Huinan, today announced an agreement to jointly develop, manufacture and distribute animal health vaccines in China. The new joint venture, Jilin Pfizer Guoyuan Animal Health Co., Ltd., will bolster the capabilities of both companies to offer a comprehensive range of vaccine products tailor

(image/jpeg)

Introducing ProNutrients™, A New Line Of Dietary Supplements From The Makers Of Centrum
Thursday September 8th 2011 11:09:00 AM

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Consumer Healthcare, makers of Centrum® multivitamins, announced today the launch of ProNutrients™, a line of supplements from the most trusted multivitamin brand helping to increase confidence in supplementing and make nutrition possible. ProNutrients is a new line of dietary supplements launched by the makers of Centrum multivitamins, and is formulated to naturally work with a multivitamin. The line includes Omega-3, Probiotic, and Fruit & Veggie—thre

(image/jpeg)

Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Thursday September 8th 2011 07:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that nine abstracts about tofacitinib (development code CP-690,550), an investigational, novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) 2011 Annual Scientific Meeting, which is being held November 5-9 in Chicago. Detailed Results Being Presented for ORAL Standard, ORAL Scan and ORAL Step ORAL Standard

(image/jpeg)

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Wednesday September 7th 2011 10:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2011 at 9:10 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link in the Investor Presentations section located on the lower right-hand corner of that

(image/jpeg)

Pfizer Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. and Commencement of Subsequent Offering Period
Tuesday September 6th 2011 08:00:00 AM

NEW YORK & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today the successful completion of the initial cash tender offer by Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), for all of the outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The initial tender offer p

(image/jpeg)

Pfizer Extends Tender Offer To Acquire Icagen, Inc.
Friday September 2nd 2011 08:00:00 AM

NEW YORK & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The tender offer is now scheduled to

(image/jpeg)

Pfizer Signs Agreement With MIT For Future Cambridge Research Center
Thursday September 1st 2011 03:45:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced it has entered into a 10-year lease agreement with the Massachusetts Institute of Technology (MIT) for more than 180,000 square feet in a new building under development in Cambridge, Massachusetts. Located at 610 Main Street South in Kendall Square, the new site will be the future location of Pfizer’s Cardiovascular, Metabolic and Endocrine Disease (CVMED) and Neuroscience Research Units. The relocation of the two Research Units will substan

Pfizer Extends Tender Offer to Acquire Icagen, Inc.
Thursday September 1st 2011 08:00:00 AM

NEW YORK and RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The tender offer is now scheduled t

(image/jpeg)

FDA Approval of XALKORI (crizotinib) and Invitation to Media Briefing from Pfizer
Monday August 29th 2011 11:38:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. has received FDA approval of XALKORI® (crizotinib) capsules – the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The effectiveness of XALKORI is based on objective response rates and, as XALKORI received accelerated approval from the FDA, Pfizer is conducting post-marketing clinical trials to further

(image/jpeg)

ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial
Sunday August 28th 2011 02:01:00 AM

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the main results of the Phase 3 clinical trial ARISTOTLE, which evaluated ELIQUIS® (apixaban) compared to warfarin for the prevention of stroke or systemic embolism in 18,201 patients with atrial fibrillation and at least one risk factor for stroke. In the ARISTOTLE trial, ELIQUIS as compared with warfarin significantly reduced the risk of stroke or systemic embolism

U.S. Food And Drug Administration Approves Pfizer’s XALKORI® (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Friday August 26th 2011 04:54:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI® (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test. The effectiveness of XALKORI is based on objective response rates (ORR) and, as XALKORI received accelerated approval from th

(image/jpeg)

Bristol-Myers Squibb And Pfizer Announce Data Presentations For Apixaban At European Society of Cardiology Congress 2011
Tuesday August 23rd 2011 07:30:00 AM

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Multiple data presentations for ELIQUIS® (apixaban), an oral direct Factor Xa inhibitor being developed by Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE), will be given at the European Society of Cardiology Congress, August 27-31, 2011, in Paris, France. Globally-conducted registrational studies evaluating ELIQUIS for the prevention of stroke in patients with atrial fibrillation will be presented during the congress. Of note is t

(image/jpeg)

Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies
Wednesday August 17th 2011 12:30:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myel

(image/jpeg)

Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies
Wednesday August 17th 2011 12:30:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myel

(image/jpeg)

Pfizer Wins Viagra Patent Trial
Monday August 15th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. in the United States District Court for the Eastern District of Virginia. "We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction," said Amy Schulman, executive vice president and general counsel for Pfizer. "Protecting the intellectual property rights of our innovativ

(image/jpeg)

Dana Delany Partners with Caltrate® to Celebrate Women and How They Move the World Every Day through Their Amazing Strength and Contributions
Wednesday August 3rd 2011 02:46:00 PM

NEW YORK--(BUSINESS WIRE)--For more than 25 years, Caltrate® has helped replenish the calcium and vitamin D women need each day in order to keep their bodies active—so they can move the world physically, emotionally and for the causes in which they believe. This year, Caltrate® is partnering with Dana Delany to celebrate women who move our world by issuing a national call-to-action inviting women everywhere to share their individual stories and everyday accomplishments. As part of this celebrati

(image/jpeg)

NCCN Receives $2M Educational Grant from Pfizer to Support Tailored Quality Improvement Plans at Leading Cancer Centers
Wednesday August 3rd 2011 10:30:00 AM

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--NCCN receives $2M educational grant from Pfizer to support first CME program to measure impact on patient outcomes & clinician performance through data collected in the NCCN Database for Breast Cancer

(image/jpeg)

Pfizer Reports Second-Quarter 2011 Results
Tuesday August 2nd 2011 07:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Second-Quarter Year-to-Date 2011 2010 Change 2011 2010 Change Reported Revenues $ 16,984 $ 17,132 (1 %) $ 33,486 $ 33,708 (1 %) Adjusted Income(2) 4,726 4,927 (4 %) 9,534 9,789 (3 %) Adjusted Diluted EPS(2) 0.60 0.61 (2 %) 1.19 1.21 (2 %) Reported Net Income(3) 2,610 2,475 5 % 4,832 4,501 7 % Reported Diluted EPS(3) 0.33 0.31 6 % 0.61 0.56 9 % See end of text prior to tables for notes.

(image/jpeg)

Pfizer Completes Sale Of Capsugel Business To KKR
Monday August 1st 2011 05:43:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, “KKR”), following the receipt of required regulatory clearances, including in the U.S. and the European Union. Under the terms of the previously announced agreement, KKR acquired the Capsugel business for $2.375 billion in cash. Pfizer’s financial advisors for the transaction were Morgan

(image/jpeg)

Pfizer Provides U.S. Regulatory Update on Prevnar 13® for Use in Adults 50 Years and Older
Friday July 29th 2011 02:19:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company’s supplemental Biologics License Application (sBLA) for use of Prevnar 13®, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults aged 50 and older. This extends the review period to January 2012. The extension is due to additional data that Pfizer elected to submit from two studies that were

(image/jpeg)

Pfizer To Acquire Icagen
Wednesday July 20th 2011 08:30:00 AM

NEW YORK, N.Y., and RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) today announced that they have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen’s fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share. The aggregate transaction value, including the value of the shares currently owned by Pfizer, is approximately $56 million. In 2007, Pfizer and

(image/jpeg)

Pfizer To Explore Strategic Alternatives For Its Animal Health And Nutrition Businesses
Thursday July 7th 2011 08:30:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value. The company is considering options that may include, among others, a full or partial separation of each of these businesses from Pfizer through a spin-off, sale or other transaction. Given the separate and distinct natu

(image/jpeg)

Positive Top-Line Results For Pfizer’s Lyrica In Phase 3 Study Of Patients With Fibromyalgia In Japan
Tuesday July 5th 2011 09:00:00 PM

TOKYO & NEW YORK--(BUSINESS WIRE)--Pfizer Japan announced today the top-line results for Lyrica (pregabalin) Study A0081208 – Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate Efficacy and Safety of Pregabalin (CI-1008) in the Treatment of Fibromyalgia. The results demonstrated a statistically significant reduction in the endpoint mean pain score, the primary efficacy analysis in the study, with pregabalin compared to placebo. Further analyses will be conducted on these

(image/jpeg)

Pfizer Affirms CHANTIX/CHAMPIX as Important Treatment Option for Smokers Wanting to Quit
Monday July 4th 2011 01:44:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer said today that the reliable science on varenicline (CHANTIX/CHAMPIX), involving more than 14 clinical trials with more than 7,000 smokers, and the medicine’s approval by regulatory authorities around the world, demonstrate the importance of the medicine as an effective and appropriate treatment option for adult smokers wanting to quit. Pfizer stands behind the benefit/risk profile of Chantix. The company expressed concerns about the reliability of the meta-anal

(image/jpeg)

Pfizer and ChemRar High Tech Center Announce Plans to Explore Innovative Medical Research and Development Partnership in Russia
Wednesday June 29th 2011 09:21:00 AM

WASHINGTON--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) announced today that they have signed a Memorandum of Understanding (MoU) to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries. The announcement was made during the BIO International Convention. The two companies will explore opportunities for accelerated development and c

(image/jpeg)

Pfizer Nutrition Data Demonstrate that Appropriate Early Child Nutrition May Be Linked to Long-Term Health Outcomes in At-Risk Populations and Picky Eaters
Wednesday June 29th 2011 08:00:00 AM

MADISON, N.J.--(BUSINESS WIRE)--Results from studies presented by Pfizer Nutrition at the 5th Europaediatrics Congress in Vienna provide further evidence that appropriate feeding practices are critical to support the healthy growth and development of at-risk infants and picky eaters facing nutritional challenges. Data from two studies presented at the Congress demonstrate that many infants and children face nutritional challenges, including those who are preterm and low-birthweight, as well as c

(image/jpeg)

Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts
Tuesday June 28th 2011 11:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 2, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Quar

(image/jpeg)

Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma
Tuesday June 28th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer’s filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC). This submission was based on Phase 3 data from the AXIS 1032 trial, comparing axitinib with sorafenib in patients with previously treated advanced RCC, which Pfizer recently presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). “This filing rep

(image/jpeg)

Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma
Tuesday June 28th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer’s filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC). This submission was based on Phase 3 data from the AXIS 1032 trial, comparing axitinib with sorafenib in patients with previously treated advanced RCC, which Pfizer recently presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). “This filing rep

(image/jpeg)

Pfizer Announces Data Presentations For Investigational Compounds In Its Lung Cancer Portfolio
Tuesday June 28th 2011 05:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 (PF-299) an investigational, oral, pan-HER inhibitor;1 and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK,2 at the International Association for the Study of Lung Cancer’s (IASLC) 14th World Conference on Lung Cancer (WCLC), July 3-7 in Amsterdam, The Netherlands. “While lung cancer remains a difficu

(image/jpeg)

FDA Complete Response Letter Received for REMOXY
Friday June 24th 2011 08:00:00 AM

NEW YORK & AUSTIN, Texas--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Pain Therapeutics, Inc. (NASDAQ: PTIE) announced that a Complete Response Letter was received from the U.S. Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY® (oxycodone) Extended-Release Capsules CII. Pfizer is working to evaluate the issues described in the Complete Response Letter and plans to have further discussions with FDA around them. REMOXY is an investigational extended-r

(image/jpeg)

Pfizer Declares A 20-Cent Third-Quarter 2011 Dividend
Thursday June 23rd 2011 04:24:00 PM

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent third-quarter 2011 dividend on the company’s common stock, payable September 6, 2011, to shareholders of record at the close of business on August 5, 2011. The third-quarter 2011 cash dividend will be the 291st consecutive quarterly dividend paid by Pfizer.

(image/jpeg)

ELIQUIS® (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study
Wednesday June 22nd 2011 07:14:00 PM

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today topline results of the Phase 3 ARISTOTLE trial of ELIQUIS®. In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, ELIQUIS met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism. In addition, ELIQUIS met the key

Pfizer’s Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord Injury
Tuesday June 21st 2011 07:30:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica Study A0081107 – Central Neuropathic Pain Following Spinal Cord Injury – demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica (pregabalin) compared to placebo. Further analysis will be conducted on these initial results. Central Neuropathic Pain is a heterogeneous group of pain conditions initiated or

(image/jpeg)

Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII
Monday June 20th 2011 07:30:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM (oxycodone HCl, USP) Tablets CII. OXECTA is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. OXECTA is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering ass

(image/jpeg)

Pfizer Injectables Adds Doxorubicin Hydrochloride Injection, USP to Its Portfolio of Off-Patent Oncology Products
Wednesday June 15th 2011 01:29:00 PM

PEAPACK, N.J.--(BUSINESS WIRE)--Pfizer Injectables, part of Pfizer Inc.’s (NYSE: PFE) Established Products Business Unit, announced today the addition of doxorubicin hydrochloride injection, USP, to Pfizer Injectables’ growing portfolio of off-patent oncology products. In March 2011, the US Food and Drug Administration (FDA) approved the reintroduction of doxorubicin hydrochloride injection, USP, in medical grade Cytosafe® polypropylene vials in the following vial sizes: 5 mL (10 mg), 10 mL (20

Pfizer Recognized By CIO Magazine As One Of The CIO 100 Award Honorees
Thursday June 9th 2011 08:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has received the 2011 CIO 100 award presented by CIO magazine. The 24th annual award program recognizes organizations around the world that exemplify the highest level of operational and strategic excellence in information technology (IT). "This year's CIO 100 awards draws well-deserved attention to companies that are not only innovating with IT but creating genuine business value as well," said Maryfran Johnson, editor in chief of C

(image/jpeg)

Boston’s Top Academic Medical Centers Join Pfizer’s Centers For Therapeutic Innovation
Wednesday June 8th 2011 02:00:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced its network of translational research partnerships, called the Centers for Therapeutic Innovation, has launched in Boston with Beth Israel Deaconess Medical Center, Boston University School of Medicine, Children’s Hospital Boston, Harvard University, Partners HealthCare, Tufts Medical Center, Tufts University, as well as University of Massachusetts Medical School in Worcester. These organizations follow on previously announced partnerships w

(image/jpeg)

Pfizer Launches “Migraines at Work” Web Site to Educate Employers and Workers about the Condition
Wednesday June 8th 2011 07:30:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has announced the launch of a web site, “Migraines at Work” (http://migrainesatwork.com), to educate U.S. employers and the public regarding one of the world’s top 20 most disabling illnesses. According to the Migraine Research Foundation1, American employers lose 113 million workdays due to Migraines per year. The Migraine Research Foundation reported an estimated 30 million Americans suffer from Migraines—which is among the world’s top 20 most

Pfizer Conducts First “Virtual” Clinical Trial Allowing Patients to Participate Regardless Of Geography
Tuesday June 7th 2011 03:00:00 PM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it is conducting the first-ever randomized clinical trial under an investigational new drug (IND) application that manages study participation entirely using electronic tools and allows patients to participate in the clinical trial regardless of their proximity to clinical sites. The pilot project, initiated following review from the U.S. Food and Drug Administration (FDA), uses mobile phone and web-based technology to collect necessary

(image/jpeg)

Pfizer to Announce New Boston-Area Research Partnerships Wednesday, June 8, 2011 2:00 p.m.
Tuesday June 7th 2011 07:39:00 AM

--(BUSINESS WIRE)--Pfizer What Major announcement concerning new network for innovative science. News will also concern Pfizer’s real estate footprint in the City of Boston Who Massachusetts Governor Deval Patrick, Boston Mayor Tom Menino, Pfizer senior executives, Boston’s top research and academic leaders When Wednesday, June 8, 2011, 2:00 p.m.Interviews immediately following announcement Where Center for Life Science BostonLongwood Medical Area3 Blackfan Circle,Boston, Mass.Ground flo

(image/jpeg)

Pfizer and Hisun Sign MOU to Increase Access to Quality and Low-Cost Medicines for Patients in China
Thursday June 2nd 2011 09:22:00 AM

SHANGHAI & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE stock code 600267), a leading pharmaceutical company in China, today jointly announced the signing of a memorandum of understanding (MOU) on their intention to establish a joint venture. This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena. Under the MOU, the two companies wi

(image/jpeg)

Pfizer Files For European Regulatory Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma
Wednesday June 1st 2011 06:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s filing for regulatory review of axitinib for patients with advanced renal cell carcinoma (RCC) after failure of prior systemic treatment. This submission was based on Phase 3 data from the AXIS 1032 trial. Pfizer will present full results from this trial, as well as additional data on axitinib, at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), being

(image/jpeg)

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Tuesday May 31st 2011 11:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mace Rothenberg, Senior Vice President, Clinical Development and Medical Affairs, Oncology Business Unit, at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011 at 3:30 p.m. Pacific Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs 32nd Annual Global Healthcare Conference” lin

(image/jpeg)

Pfizer Invites Public to View and Listen to Webcast of June 6 Pfizer Analyst and Investor Meeting at ASCO
Tuesday May 31st 2011 10:00:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s oncology leadership team at an analyst and investor meeting on Monday, June 6, 2011 at 6:00 p.m. Central Daylight Saving Time, in connection with the annual meeting of the American Society of Clinical Oncology (ASCO). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Analyst and Investor Meeting at ASCO” link

(image/jpeg)

Pfizer Announces New Strategic Partnerships With ICON And PAREXEL International Corporation
Thursday May 26th 2011 08:30:00 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced strategic partnerships with ICON plc and PAREXEL International Corporation, both of which will serve as strategic providers of clinical trial implementation services over a five-year period beginning in June 2011. The new partnerships will be fully implemented over an 18-to-24 month period. The ICON and PAREXEL alliances reflect Pfizer’s recent commitment to strengthen the performance of its innovative core. Pfizer announced in February a co

Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions
Wednesday May 25th 2011 08:03:00 AM

THOUSAND OAKS, Calif. and NEW YORK--(BUSINESS WIRE)--Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (P

Wyeth (WYE)

Business Wire

Pfizer Receives FDA Approval to Extend Use of Prevnar 13® for Prevention of Pneumococcal Pneumonia and Invasive Disease in Adults 50 Years and OlderFriday December 30th 2011 03:47:00 PM

Pfizer Reports Results From Three Phase 4 Studies Demonstrating EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact On Drug Liking And Withdrawal SymptomsThursday December 22nd 2011 08:00:00 AM

Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With AnalystsTuesday December 20th 2011 10:00:00 AM

Pfizer Announces FDA Acceptance For Review Of New Drug Application For Tofacitinib For Adult Patients With Moderately To Severely Active Rheumatoid ArthritisTuesday December 20th 2011 08:00:00 AM

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Restless Legs SyndromeFriday December 16th 2011 08:00:00 AM

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabaline) Capsules CV In Restless Legs SyndromeFriday December 16th 2011 08:00:00 AM

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (prebabalin) Capsules CV In Restless Legs SyndromeFriday December 16th 2011 08:00:00 AM

Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest CountriesFriday December 16th 2011 07:00:00 AM

Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest CountriesFriday December 16th 2011 07:00:00 AM

New Survey Reveals Top Misperceptions Parents Have When Treating Their Child’s FeverTuesday December 13th 2011 08:00:00 AM

Pfizer Elects CEO Ian Read As Chairman Of The BoardMonday December 12th 2011 03:16:00 PM

Pfizer Declares A 22-Cent First-Quarter 2012 DividendMonday December 12th 2011 11:24:00 AM

Jon Bon Jovi Reveals His True Advil® StoryFriday December 9th 2011 08:01:00 AM

Jon Bon Jovi Reveals His True Advil® StoryThursday December 8th 2011 08:01:00 PM

The Advil® Congestion Relief Project Tackles Congestion in Chicago, the Country’s #1 City for Traffic Congestion*Thursday December 8th 2011 10:08:00 AM

FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma (RCC) To Be FavorableWednesday December 7th 2011 11:42:00 AM

Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly PatientsMonday December 5th 2011 05:03:00 PM

Pfizer Completes Acquisition of ExcaliardFriday December 2nd 2011 08:00:00 AM

Pfizer Completes Acquisition of Ferrosan Consumer Health’s BusinessThursday December 1st 2011 05:30:00 AM

New Research Initiative Examines Economic Impact of Smoke-free Policies on Restaurants and BarsWednesday November 30th 2011 04:26:00 PM

FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial FibrillationTuesday November 29th 2011 09:14:00 AM

Pfizer to Acquire Excaliard PharmaceuticalsTuesday November 22nd 2011 07:30:00 AM

Pfizer And MIT Break Ground On New Research Units In Kendall SquareMonday November 21st 2011 11:00:00 AM

Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid ArthritisMonday November 21st 2011 05:00:00 AM

Pfizer Wins Corporate Citizenship Award For Global Health Partnerships ProgramFriday November 18th 2011 09:28:00 AM

Pfizer’s Vyndaqel® (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)Thursday November 17th 2011 06:00:00 AM

The Advil® Congestion Relief Project Hits the Road to Relieve Congestion in CommunitiesWednesday November 16th 2011 12:37:00 PM

Kathryn Joosten Speaks Out About Lung Cancer Profiles; ‘Desperate’ to Share Her Personal Lung Cancer Story to Help OthersMonday November 14th 2011 01:01:00 PM

New Data Presented On Phase 3 Trial Of ELIQUIS® (apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical IllnessSunday November 13th 2011 08:01:00 AM

Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary UrgencyTuesday November 8th 2011 07:00:00 AM

Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd Annual Meeting Of The American Society Of HematologyMonday November 7th 2011 02:00:00 PM

Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients with Moderately Active DiseaseSaturday November 5th 2011 05:20:00 PM

Pfizer Reports Third-Quarter 2011 ResultsTuesday November 1st 2011 07:00:00 AM

Pfizer Reports Third-Quarter 2011 ResultsTuesday November 1st 2011 07:00:00 AM

Pfizer Completes Acquisition Of IcagenFriday October 28th 2011 08:00:00 AM

Pfizer Declares A 20-Cent Fourth-Quarter 2011 DividendThursday October 27th 2011 09:37:00 AM

Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal DiseaseThursday October 27th 2011 05:00:00 AM

Pfizer Establishes Precision Medicine Research Collaboration With MedcoWednesday October 26th 2011 04:00:00 PM

Peggy Fleming and the Makers of Robitussin® Provide Relief this Cold and Flu Season with a Simple Question: "Does Your Last Name Sound Contagious?"Wednesday October 26th 2011 09:25:00 AM

Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:SearchWednesday October 26th 2011 08:00:00 AM

Pfizer Invites Public to View and Listen to Webcast of November 6 Pfizer Analyst and Investor Meeting at ACRMonday October 24th 2011 10:00:00 AM

Additional Data From Pfizer’s Prevnar 13® Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of AmericaFriday October 21st 2011 08:00:00 AM

Pfizer Animal Health and the Resource Foundation Expand Initiative to Increase Productivity of Small Family Farms in Latin America and IndiaTuesday October 18th 2011 08:00:00 AM

Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for SeniorsThursday October 13th 2011 03:00:00 PM

Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER InhibitorWednesday October 5th 2011 05:01:00 PM

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With AnalystsMonday October 3rd 2011 10:00:00 AM

Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award CeremonyFriday September 30th 2011 05:36:00 PM

Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND® (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive AspergillosisFriday September 30th 2011 08:00:00 AM

The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines OnlineThursday September 29th 2011 09:06:00 AM

Even Famous Faces Have an Advil® Story to ShareThursday September 22nd 2011 10:52:00 AM

New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial HyperplasiaThursday September 22nd 2011 08:00:00 AM

Pfizer Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc.Tuesday September 20th 2011 08:00:00 AM

Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.Tuesday September 13th 2011 08:00:00 AM

Pfizer to Present Clinical Data from Oncology Portfolio at the 2011 European Multidisciplinary Cancer CongressTuesday September 13th 2011 06:00:00 AM

Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In ChinaThursday September 8th 2011 05:01:00 PM

Introducing ProNutrients™, A New Line Of Dietary Supplements From The Makers Of CentrumThursday September 8th 2011 11:09:00 AM

Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific MeetingThursday September 8th 2011 07:00:00 AM

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare ConferenceWednesday September 7th 2011 10:00:00 AM

Pfizer Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. and Commencement of Subsequent Offering PeriodTuesday September 6th 2011 08:00:00 AM

Pfizer Extends Tender Offer To Acquire Icagen, Inc.Friday September 2nd 2011 08:00:00 AM

Pfizer Signs Agreement With MIT For Future Cambridge Research CenterThursday September 1st 2011 03:45:00 PM

Pfizer Extends Tender Offer to Acquire Icagen, Inc.Thursday September 1st 2011 08:00:00 AM

FDA Approval of XALKORI (crizotinib) and Invitation to Media Briefing from PfizerMonday August 29th 2011 11:38:00 AM

ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE TrialSunday August 28th 2011 02:01:00 AM

U.S. Food And Drug Administration Approves Pfizer’s XALKORI® (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung CancerFriday August 26th 2011 04:54:00 PM

Bristol-Myers Squibb And Pfizer Announce Data Presentations For Apixaban At European Society of Cardiology Congress 2011Tuesday August 23rd 2011 07:30:00 AM

Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer TherapiesWednesday August 17th 2011 12:30:00 PM

Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer TherapiesWednesday August 17th 2011 12:30:00 PM

Pfizer Wins Viagra Patent TrialMonday August 15th 2011 08:00:00 AM

Dana Delany Partners with Caltrate® to Celebrate Women and How They Move the World Every Day through Their Amazing Strength and ContributionsWednesday August 3rd 2011 02:46:00 PM

NCCN Receives $2M Educational Grant from Pfizer to Support Tailored Quality Improvement Plans at Leading Cancer CentersWednesday August 3rd 2011 10:30:00 AM

Pfizer Reports Second-Quarter 2011 ResultsTuesday August 2nd 2011 07:00:00 AM

Pfizer Completes Sale Of Capsugel Business To KKRMonday August 1st 2011 05:43:00 PM

Pfizer Provides U.S. Regulatory Update on Prevnar 13® for Use in Adults 50 Years and OlderFriday July 29th 2011 02:19:00 PM

Pfizer To Acquire IcagenWednesday July 20th 2011 08:30:00 AM

Pfizer To Explore Strategic Alternatives For Its Animal Health And Nutrition BusinessesThursday July 7th 2011 08:30:00 AM

Positive Top-Line Results For Pfizer’s Lyrica In Phase 3 Study Of Patients With Fibromyalgia In JapanTuesday July 5th 2011 09:00:00 PM

Pfizer Affirms CHANTIX/CHAMPIX as Important Treatment Option for Smokers Wanting to QuitMonday July 4th 2011 01:44:00 PM

Pfizer Receives FDA Approval to Extend Use of Prevnar 13® for Prevention of Pneumococcal Pneumonia and Invasive Disease in Adults 50 Years and Older
Friday December 30th 2011 03:47:00 PM

Pfizer Reports Results From Three Phase 4 Studies Demonstrating EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact On Drug Liking And Withdrawal Symptoms
Thursday December 22nd 2011 08:00:00 AM

Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts
Tuesday December 20th 2011 10:00:00 AM

Pfizer Announces FDA Acceptance For Review Of New Drug Application For Tofacitinib For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Tuesday December 20th 2011 08:00:00 AM

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Restless Legs Syndrome
Friday December 16th 2011 08:00:00 AM

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabaline) Capsules CV In Restless Legs Syndrome
Friday December 16th 2011 08:00:00 AM

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (prebabalin) Capsules CV In Restless Legs Syndrome
Friday December 16th 2011 08:00:00 AM

Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries
Friday December 16th 2011 07:00:00 AM

Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries
Friday December 16th 2011 07:00:00 AM

New Survey Reveals Top Misperceptions Parents Have When Treating Their Child’s Fever
Tuesday December 13th 2011 08:00:00 AM

Pfizer Elects CEO Ian Read As Chairman Of The Board
Monday December 12th 2011 03:16:00 PM

Pfizer Declares A 22-Cent First-Quarter 2012 Dividend
Monday December 12th 2011 11:24:00 AM

Jon Bon Jovi Reveals His True Advil® Story
Friday December 9th 2011 08:01:00 AM

Jon Bon Jovi Reveals His True Advil® Story
Thursday December 8th 2011 08:01:00 PM

The Advil® Congestion Relief Project Tackles Congestion in Chicago, the Country’s #1 City for Traffic Congestion*
Thursday December 8th 2011 10:08:00 AM

FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma (RCC) To Be Favorable
Wednesday December 7th 2011 11:42:00 AM

Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
Monday December 5th 2011 05:03:00 PM

Pfizer Completes Acquisition of Excaliard
Friday December 2nd 2011 08:00:00 AM

Pfizer Completes Acquisition of Ferrosan Consumer Health’s Business
Thursday December 1st 2011 05:30:00 AM

New Research Initiative Examines Economic Impact of Smoke-free Policies on Restaurants and Bars
Wednesday November 30th 2011 04:26:00 PM

FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Tuesday November 29th 2011 09:14:00 AM

Pfizer to Acquire Excaliard Pharmaceuticals
Tuesday November 22nd 2011 07:30:00 AM

Pfizer And MIT Break Ground On New Research Units In Kendall Square
Monday November 21st 2011 11:00:00 AM

Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis
Monday November 21st 2011 05:00:00 AM

Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program
Friday November 18th 2011 09:28:00 AM

Pfizer’s Vyndaqel® (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)
Thursday November 17th 2011 06:00:00 AM

The Advil® Congestion Relief Project Hits the Road to Relieve Congestion in Communities
Wednesday November 16th 2011 12:37:00 PM

Kathryn Joosten Speaks Out About Lung Cancer Profiles; ‘Desperate’ to Share Her Personal Lung Cancer Story to Help Others
Monday November 14th 2011 01:01:00 PM

New Data Presented On Phase 3 Trial Of ELIQUIS® (apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical Illness
Sunday November 13th 2011 08:01:00 AM

Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency
Tuesday November 8th 2011 07:00:00 AM

Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd Annual Meeting Of The American Society Of Hematology
Monday November 7th 2011 02:00:00 PM

Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients with Moderately Active Disease
Saturday November 5th 2011 05:20:00 PM

Pfizer Reports Third-Quarter 2011 Results
Tuesday November 1st 2011 07:00:00 AM

Pfizer Reports Third-Quarter 2011 Results
Tuesday November 1st 2011 07:00:00 AM

Pfizer Completes Acquisition Of Icagen
Friday October 28th 2011 08:00:00 AM

Pfizer Declares A 20-Cent Fourth-Quarter 2011 Dividend
Thursday October 27th 2011 09:37:00 AM

Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease
Thursday October 27th 2011 05:00:00 AM

Pfizer Establishes Precision Medicine Research Collaboration With Medco
Wednesday October 26th 2011 04:00:00 PM

Peggy Fleming and the Makers of Robitussin® Provide Relief this Cold and Flu Season with a Simple Question: "Does Your Last Name Sound Contagious?"
Wednesday October 26th 2011 09:25:00 AM

Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search
Wednesday October 26th 2011 08:00:00 AM

Pfizer Invites Public to View and Listen to Webcast of November 6 Pfizer Analyst and Investor Meeting at ACR
Monday October 24th 2011 10:00:00 AM

Additional Data From Pfizer’s Prevnar 13® Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of America
Friday October 21st 2011 08:00:00 AM

Pfizer Animal Health and the Resource Foundation Expand Initiative to Increase Productivity of Small Family Farms in Latin America and India
Tuesday October 18th 2011 08:00:00 AM

Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for Seniors
Thursday October 13th 2011 03:00:00 PM

Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor
Wednesday October 5th 2011 05:01:00 PM

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts
Monday October 3rd 2011 10:00:00 AM

Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award Ceremony
Friday September 30th 2011 05:36:00 PM

Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND® (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive Aspergillosis
Friday September 30th 2011 08:00:00 AM

The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online
Thursday September 29th 2011 09:06:00 AM

Even Famous Faces Have an Advil® Story to Share
Thursday September 22nd 2011 10:52:00 AM

New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial Hyperplasia
Thursday September 22nd 2011 08:00:00 AM

Pfizer Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc.
Tuesday September 20th 2011 08:00:00 AM

Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.
Tuesday September 13th 2011 08:00:00 AM

Pfizer to Present Clinical Data from Oncology Portfolio at the 2011 European Multidisciplinary Cancer Congress
Tuesday September 13th 2011 06:00:00 AM

Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In China
Thursday September 8th 2011 05:01:00 PM

Introducing ProNutrients™, A New Line Of Dietary Supplements From The Makers Of Centrum
Thursday September 8th 2011 11:09:00 AM

Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Thursday September 8th 2011 07:00:00 AM

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Wednesday September 7th 2011 10:00:00 AM

Pfizer Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. and Commencement of Subsequent Offering Period
Tuesday September 6th 2011 08:00:00 AM

Pfizer Extends Tender Offer To Acquire Icagen, Inc.
Friday September 2nd 2011 08:00:00 AM

Pfizer Signs Agreement With MIT For Future Cambridge Research Center
Thursday September 1st 2011 03:45:00 PM

Pfizer Extends Tender Offer to Acquire Icagen, Inc.
Thursday September 1st 2011 08:00:00 AM

FDA Approval of XALKORI (crizotinib) and Invitation to Media Briefing from Pfizer
Monday August 29th 2011 11:38:00 AM

ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial
Sunday August 28th 2011 02:01:00 AM

U.S. Food And Drug Administration Approves Pfizer’s XALKORI® (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Friday August 26th 2011 04:54:00 PM

Bristol-Myers Squibb And Pfizer Announce Data Presentations For Apixaban At European Society of Cardiology Congress 2011
Tuesday August 23rd 2011 07:30:00 AM

Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies
Wednesday August 17th 2011 12:30:00 PM

Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies
Wednesday August 17th 2011 12:30:00 PM

Pfizer Wins Viagra Patent Trial
Monday August 15th 2011 08:00:00 AM

Dana Delany Partners with Caltrate® to Celebrate Women and How They Move the World Every Day through Their Amazing Strength and Contributions
Wednesday August 3rd 2011 02:46:00 PM

NCCN Receives $2M Educational Grant from Pfizer to Support Tailored Quality Improvement Plans at Leading Cancer Centers
Wednesday August 3rd 2011 10:30:00 AM

Pfizer Reports Second-Quarter 2011 Results
Tuesday August 2nd 2011 07:00:00 AM

Pfizer Completes Sale Of Capsugel Business To KKR
Monday August 1st 2011 05:43:00 PM

Pfizer Provides U.S. Regulatory Update on Prevnar 13® for Use in Adults 50 Years and Older
Friday July 29th 2011 02:19:00 PM

Pfizer To Acquire Icagen
Wednesday July 20th 2011 08:30:00 AM

Pfizer To Explore Strategic Alternatives For Its Animal Health And Nutrition Businesses
Thursday July 7th 2011 08:30:00 AM

Positive Top-Line Results For Pfizer’s Lyrica In Phase 3 Study Of Patients With Fibromyalgia In Japan
Tuesday July 5th 2011 09:00:00 PM

Pfizer Affirms CHANTIX/CHAMPIX as Important Treatment Option for Smokers Wanting to Quit
Monday July 4th 2011 01:44:00 PM

Pfizer and ChemRar High Tech Center Announce Plans to Explore Innovative Medical Research and Development Partnership in Russia
Wednesday June 29th 2011 09:21:00 AM

Pfizer Nutrition Data Demonstrate that Appropriate Early Child Nutrition May Be Linked to Long-Term Health Outcomes in At-Risk Populations and Picky Eaters
Wednesday June 29th 2011 08:00:00 AM